Abbott signs licensing, supply deal with Zydus Cadila

12 May 2010 Evaluate

US-based drug maker Abbott has signed a licensing and supply agreement with Zydus Cadila for 24 products to be sold in 15 emerging markets. The collaboration includes medicines for pain, cancer and cardiovascular, neurological and respiratory diseases. The partnership will leverage Abbott's powerful emerging markets infrastructure to commercialize the Zydus products, with product launches beginning in early 2012.

Under the agreement, Abbott will gain rights to at least 24 Zydus products in 15 key emerging markets where Abbott has a strong and growing presence. The agreement also includes an option for the addition of more than 40 Zydus products to the collaboration.

Pharmaceutical sales in emerging markets, including India, China and Brazil are expected to grow at three times the rate of developed markets. As per the industry estimates, the total market for pharmaceutical products is around $600 billion.crackcrack

Abbott India Share Price

30999.30 1420.70 (4.80%)
15-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1705.15
Dr. Reddys Lab 1155.80
Cipla 1481.40
Lupin 2012.05
Zydus Lifesciences 884.20
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...